PharmaTelevision - Roche's Approach to Partnering

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Roche's Approach to Partnering

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Bardia Akbari, Global Head Partnering of Inflammation, Respiratory, and Ophthalmology at Roche

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Strategy of partnering

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at Bio-Europe in Milan, in spring 2011. On this show I have Bardia Akbari, who is Global Head of Partnering at Roche specializing in inflammation, respiratory and ophthalmology , welcome to the show.

Bardia Akbari:

Thank you very much.

Fintan Walton:

Bardia, you cover a broad range of therapeutic areas each of them are very specialized, each of them are fundamental to for certain therapeutic areas what's important about each of those areas of course is how we understand the underlying causes of those particular diseases, so somebody who is involved in business development and partnering for Roche what is your strategy for partnering?

Bardia Akbari:

The strategy for partnering for all the diseases that we talked about here there is an immunological underlying and underterm, so if you look at the immunology and look at the basic science for all these diseases at some point they share a pathway, they share a target and they eventually come together, so it's important to understand immunology and the basic immunology and the pathology as related to the immunology it's diseases and then from there you can move on to any specific disease and go to a different pathway and different ways to pursue opportunity for each one, but I would say again the basic understanding of immunology is key for all the diseases that we oversee in this group.

Fintan Walton:

So then from a strategic point of view you need to access the fundamental science that gives us a better insight into the underlying causes of the disease, but at the same time obviously you are trying to fill a pipeline?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Bardia Akbari

Global Head Partnering

Dr. Bardia Akbari , serves as Global Head Partnering at Roche Partnering in Switzerland, overseeing many of the key global alliances focused on inflammatory disease. His previous positions include: Global Study Manager and Clinical Operations Manger at Roche. Whilst conducting his post-doctoral fellowship at Rutgers he additionally ran the US clinical trials within Roche Medical Affairs. As such he has gained extensive experience in global responsibility of planning and carrying out clinical development programs for new compounds to treat auto-immune diseases.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Roche

Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employee worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.